What each state’s law does when the FDA approves a psilocybin medicine

No psilocybin medicine is approved. When one is, it stays in federal Schedule I until the DEA issues a rule, and each state’s own law decides how it treats that one prescription drug. None of these laws changes anything for psilocybin mushrooms.

Tracker · Updated 20 Nov 2026 · Each row carries the date its statute was read

State by state, and the federal step

Eleven states have enacted a measure on what their drug schedules do once the FDA approves a psilocybin medicine. Most states also have an older, general clause that ties their schedules to a federal change, and those clauses differ in who acts, whether they must, how long they wait, and whether they reach a move to a lower schedule at all. Each row says which, in the statute’s own terms.

Each statute was read on its state’s own code or legislature host. Open a row’s “Its own words” to see the text the row rests on. A place’s name links to its register record.

Find a state All fifty and the District of Columbia, A to Z.
What each jurisdiction's law does when the FDA approves a psilocybin medicine, what it waits on, where it stands, the statute and the date it was read.
JurisdictionWhat its law does on approvalWhat it waits onWhere it standsThe statuteChecked
The federal step
Federal lawAfter FDA approval, the DEA must issue an interim final rule within 90 days of the later of HHS's recommendation and notice of approval. The medicine stays in Schedule I until that rule, and the approval letter decides whether approval itself waits for it.FDA approval, then DEA ruleThe sponsor says it completed its application on 9 November 2026. The FDA's 2026 approvals list, current to 19 November, names no psilocybin medicine.21 U.S.C. 811(j) (opens in new tab)21 U.S.C. 355(x) (opens in new tab)21 CFR 1308.11 (opens in new tab)
Its own words

21 U.S.C. 811(j)(1): if the Secretary of Health and Human Services recommends that the Attorney General control the drug in schedule II, III, IV, or V pursuant to subsections (a) and (b), the Attorney General shall, not later than 90 days after the date described in paragraph (2), issue an interim final rule controlling the drug

21 U.S.C. 355(x)(1): approval of such application shall not take effect until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act

The fifty states and the District of Columbia
AlabamaThe State Board of Health must follow a federal rescheduling 30 days after the DEA's final order appears in the Federal Register, once notified, unless it objects. The text does not say if an interim final rule counts as a final order.DEA rule, then State Board of HealthWaiting on an FDA approval.Ala. Code 20-2-20(c) (opens in new tab)
Its own words

Ala. Code 20-2-20(c): If any substance is designated, rescheduled, or deleted as a controlled substance under federal law ... the State Board of Health shall similarly control the substance under this chapter after the expiration of 30 days from publication in the federal register of a final order ... unless within that 30-day period, the State Board of Health objects

AlaskaThe clause reaches only a substance newly added as a controlled substance under federal law. Even for that, it obliges the governor only to introduce a bill in the legislature.DEA rule, then the legislatureWaiting on an FDA approval.AS 11.71.120(b) (opens in new tab)
Its own words

AS 11.71.120(b): (b) If a substance is added as a controlled substance under federal law, the governor shall introduce legislation in accordance with the federal law.

ArizonaSince September 2026, any FDA-approved product the DEA schedules or reschedules takes the identical schedule in Arizona's controlled substances chapter, with no Board action, and may be prescribed once outside Schedule I. Title 13 still lists psilocybin as a dangerous drug. Its section 13-3412(A)(7) exempts from section 13-3407, the dangerous-drug offense, a person lawfully holding a controlled substance that chapter authorizes.DEA ruleSB 1188 in force since 12 September 2026. A 2025 provision for crystalline polymorph psilocybin (SB 1555) takes effect only if the federal steps come by 1 January 2031. Waiting on an FDA approval.A.R.S. 36-2517.03 (opens in new tab)SB 1188 (2026), Laws 2026 ch. 216 (opens in new tab)A.R.S. 13-3412(A)(7) (opens in new tab)A.R.S. 36-2517.02 (opens in new tab)SB 1555 (2025), Laws 2025 ch. 231 (opens in new tab)
Its own words

A.R.S. 36-2517.03: Notwithstanding any other provision of this chapter to the contrary, without any further action by the board: 1. Any compound, mixture or preparation that is approved by the United States food and drug administration and that is scheduled or rescheduled by the United States drug enforcement administration is assigned the identical schedule under this chapter.

A.R.S. 13-3412(A)(7): 7. Persons lawfully in possession or control of controlled substances authorized by title 36, chapter 27 or the rules adopted pursuant to title 36, chapter 27.

A.R.S. 36-2517.02: Any pharmaceutical composition of crystalline polymorph psilocybin that is approved by the United States food and drug administration and rescheduled by the United States drug enforcement administration to a schedule other than schedule I of the controlled substances act ... is a controlled substance for the purposes of this chapter and may be prescribed in this state.

ArkansasThe 30-day duty reaches only a substance newly designated as controlled under federal law. A move to a lower schedule is left to the Secretary of the Department of Health, who may reschedule by rule.DEA rule, then Secretary of HealthWaiting on an FDA approval.Ark. Code 5-64-201(d) (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.
Its own words

Ark. Code 5-64-201(d)(1): If any substance is designated as a controlled substance under federal law and notice of the designation is given to the secretary, the secretary shall similarly control the substance under this chapter after the expiration of thirty (30) days from publication in the Federal Register of a final order designating a substance as a controlled substance

Ark. Code 5-64-201(a)(1)(A)(i): (i) The Secretary of the Department of Health shall administer this chapter and may add a substance to or delete or reschedule any substance enumerated in a schedule under the procedures of the Arkansas Administrative Procedure Act, § 25-15-201 et seq.

CaliforniaOnce a federal rescheduling places an FDA-approved product outside Schedule I, prescribers and pharmacists acting under federal law are deemed to comply with state law. Psilocybin stays in state Schedule I, and the text leaves open whether patients are covered if only the product moves.DEA rulePrinted as current law in the Board of Pharmacy's 2026 lawbook. Waiting on an FDA approval.Cal. Health & Safety Code 11150.3 (opens in new tab)Cal. Health & Safety Code 11054(d) (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.
Its own words

Cal. Health & Safety Code 11150.3(a): if a product composed of one of these substances is approved by the federal Food and Drug Administration and either placed on a schedule of the act other ... than Schedule I ... the physician, pharmacist, ... who prescribes, furnishes, or dispenses that product in accordance with federal law shall be deemed to be in compliance with state law governing those acts.

ColoradoSince August 2026, Colorado controls an FDA-approved prescription drug product as the DEA does, automatically and immediately from the DEA's effective date. Once the DEA places it outside Schedule I, it leaves Colorado's Schedule I if dispensed by a registered pharmacy or administered by a practitioner, and possessed only by an authorized person.DEA ruleIn force since August 2026 (SB 26-031) and separate from Colorado's natural medicine program. Waiting on an FDA approval.C.R.S. 18-18-203(3), SB 26-031 (2026) (opens in new tab)HB 25-1063 (2025), C.R.S. 18-18-203(2)(c)(XXI) (opens in new tab)
Its own words

C.R.S. 18-18-203(3)(a): NOTWITHSTANDING SUBSECTION (1) OR (2) OF THIS SECTION, A CONTROLLED SUBSTANCE LISTED ON SCHEDULE I PURSUANT TO THIS SECTION DOES NOT INCLUDE A PRESCRIPTION DRUG PRODUCT CONTAINING THE SCHEDULE I CONTROLLED SUBSTANCE IF THE PRESCRIPTION DRUG PRODUCT IS: (I) APPROVED FOR PRESCRIPTION USE BY THE FEDERAL FOOD AND DRUG ADMINISTRATION AND DESIGNATED OR RESCHEDULED BY THE FEDERAL DRUG ENFORCEMENT ADMINISTRATION ON A SCHEDULE OTHER THAN SCHEDULE I

C.R.S. 18-18-203(3)(b): A PRESCRIPTION DRUG PRODUCT CONTAINING A SCHEDULE I CONTROLLED SUBSTANCE THAT IS APPROVED FOR PRESCRIPTION USE BY THE FEDERAL FOOD AND DRUG ADMINISTRATION MUST BE CONTROLLED IN COLORADO IN THE SAME MANNER AS THE PRODUCT IS CONTROLLED BY THE FEDERAL DRUG ENFORCEMENT ADMINISTRATION

C.R.S. 18-18-203(3)(c): THE DESIGNATION OR RESCHEDULING OF A PRESCRIPTION DRUG PRODUCT IN COLORADO IS AUTOMATICALLY AND IMMEDIATELY EFFECTIVE UPON THE EFFECTIVE DATE OF THE FEDERAL DRUG ENFORCEMENT ADMINISTRATION'S DESIGNATION OR RESCHEDULING

ConnecticutFederal schedules prevail automatically only where they are stricter, so a federal move to a lower schedule does not carry over if Connecticut's regulations place the drug in Schedule I. The Commissioner of Consumer Protection may change its schedule by regulation.DEA rule, then Commissioner of Consumer ProtectionWaiting on an FDA approval.Conn. Gen. Stat. 21a-243(g) (opens in new tab)Conn. Gen. Stat. 21a-243(d) (opens in new tab)
Its own words

Conn. Gen. Stat. 21a-243(g): In the event of any inconsistency between ... schedules I, II, III, IV and V of the federal Controlled Substances Act, as amended, the provisions of the federal act shall prevail, except (1) when the provisions of the Connecticut controlled substance scheduling regulations place a controlled substance in a schedule with a higher numerical designation, schedule I being the highest designation

Conn. Gen. Stat. 21a-243(d): (d) The Commissioner of Consumer Protection may by regulation change the schedule in which a substance classified as a controlled substance in schedules I to V of the controlled substance scheduling regulations is placed.

DelawareThe Secretary of State may reschedule a substance only after the federal schedules change and the chapter's placement findings are made, with no time limit. Psilocybin stays in Schedule I by statute until then.DEA rule, then Secretary of StateWaiting on an FDA approval.16 Del. C. 4711 (opens in new tab)
Its own words

16 Del. C. 4711: the Secretary may delete or reschedule substances enumerated in the schedules of controlled substances only if: (1) Such substances have been deleted from or rescheduled within the federal schedules of controlled substances by the Attorney General of the United States ... (2) The findings required by this chapter for placement of substances in the schedules of controlled substances have been made.

District of ColumbiaThe Mayor may follow a federal rescheduling, with no time limit and no automatic effect, and the text does not say whether a rule is needed to do so. Psilocybin stays in Schedule I by statute until the Mayor acts.DEA rule, then the MayorWaiting on an FDA approval.D.C. Code 48-902.01(d) (opens in new tab)
Its own words

D.C. Code 48-902.01(d): (d) If any substance is designated, rescheduled, or deleted as a controlled substance under federal law, the Mayor may similarly designate, reschedule, or delete the controlled substance under this chapter, or may otherwise designate, reschedule or delete as a controlled substance pursuant to subsections (a) and (b) of this section.

FloridaFlorida's Attorney General may, by rule, move a substance to a less controlled schedule on finding that reduced control is in the public interest, giving great weight to federal scheduling. Short of a new statute, that rule is the only route.DEA rule, then state Attorney GeneralWaiting on an FDA approval.Fla. Stat. 893.0355(2) (opens in new tab)
Its own words

Fla. Stat. 893.0355(2): The Attorney General is hereby delegated the authority to adopt rules rescheduling specified substances to a less controlled schedule, or deleting specified substances from a schedule, upon a finding that reduced control of such substances is in the public interest.

Fla. Stat. 893.0355(3): the Attorney General shall give great weight to the scheduling rules adopted by the United States Attorney General subsequent to such substances being listed in Schedules I, II, III, IV, and V hereof

GeorgiaOnce an FDA-approved crystalline polymorph psilocybin drug is DEA-scheduled and listed in 21 U.S.C. 812, it leaves Georgia's Schedule I psilocybin entry. The text names no Georgia schedule for it and does not say if a DEA rule counts as listing in 812.DEA ruleSigned in 2026. The psilocybin section takes effect only once the drug is FDA-approved, DEA-scheduled and listed in 21 U.S.C. 812.O.C.G.A. 16-13-22(a) (opens in new tab)HB 382 (2026), Sections 3 and 8 (opens in new tab)Read on the Board of Pharmacy's reprint; the official code host refused automated readers.
Its own words

HB 382 (2026), Section 3: Such term does not include a drug containing crystalline polymorph ... psilocybin that is approved by the federal Food and Drug Administration under Section ... 505 of the federal Food, Drug, and Cosmetic Act

HB 382 (2026), Section 8(b): Section 3 of this Act shall become effective only if ... scheduled in accordance with its ... scheduling by the United States Drug Enforcement Administration, and listed in the federal ... Controlled Substances Act, 21 U.S.C. Section 812.

HawaiiOnce notified, the Department of Law Enforcement must follow a federal rescheduling 30 days after the DEA's final order is published, if an interim final rule counts as one. The change is temporary and is nullified unless the next regular legislative session enacts it.DEA rule, then Department of Law EnforcementWaiting on an FDA approval. SB 3199, which would have covered interim final orders, died in conference in 2026.Haw. Rev. Stat. 329-11(d) (opens in new tab)SB 3199 (2026), died in conference (opens in new tab)
Its own words

Haw. Rev. Stat. 329-11(d): The department of law enforcement shall similarly designate the substance as added, deleted, or rescheduled under this chapter, after the expiration of thirty days from publication in the Federal Register of a final order, and this change shall have the effect of law.

Haw. Rev. Stat. 329-11(d): the control shall be temporary and, if the next regular session of the state legislature has not made the corresponding changes in this chapter, the temporary designation of the added, deleted, or rescheduled substance shall be nullified.

IdahoThe board must follow a federal rescheduling within 30 days of the DEA's final order being published, by temporary rule or a proposed statutory amendment, unless it objects. The text does not say if an interim final rule counts as a final order.DEA rule, then the boardWaiting on an FDA approval.Idaho Code 37-2702(d) (opens in new tab)
Its own words

Idaho Code 37-2702(d): the board shall similarly control the substance under this act by promulgating a temporary rule or proposing a statutory amendment, or both, within thirty (30) days from publication in the federal register of a final order ... unless within that thirty (30) day period, the board objects to inclusion, rescheduling, or deletion.

IllinoisA federal rescheduling is deemed to apply 30 days after the DEA's final order is published, even without Department action, unless the Department or an adversely affected party objects, which brings a public hearing within 45 days and a decision within 14 days of it. The text does not say if an interim final rule counts as a final order.DEA ruleThe day-30 rule has been in force since 7 August 2026 (P.A. 104-0819). Waiting on an FDA approval.720 ILCS 570/201(d) (opens in new tab)P.A. 104-0819 (2026) (opens in new tab)
Its own words

720 ILCS 570/201(d): If the Department does not take action within 30 days, at the conclusion of the 30-day period the substance shall be considered scheduled, rescheduled, or deleted in the same manner as the federal law, unless within that 30-day period the Department objects, or a party adversely affected files with the Department substantial written objections

IndianaA federal move to a less restrictive schedule follows automatically, with no state act. If the board objects within 30 days of the federal change, the move is held until the end of the next complete session of the General Assembly.DEA ruleWaiting on an FDA approval.Ind. Code 35-48-2-1(e) (opens in new tab)
Its own words

Ind. Code 35-48-2-1(e): (e) If a substance is rescheduled to a less restrictive schedule or deleted as a controlled substance under federal law, the substance is rescheduled or deleted under this article.

Ind. Code 35-48-2-1(e): If the ... board objects to inclusion, rescheduling, or deletion of the substance, the board shall notify the chairman of the legislative council not more than thirty (30) days after the federal law is changed and the substance may not be rescheduled or deleted until the conclusion of the next complete session of the general assembly.

IowaThe 30-day duty covers only a new substance designated under federal law. A move to a lower schedule goes to the General Assembly as the board's recommendation, so the schedule changes only by statute.DEA rule, then the legislatureWaiting. HF 383, which would have moved the approved drug out of Schedule I, passed both chambers and was vetoed on 11 June 2025.Iowa Code 124.201(4) (opens in new tab)HF 383 (2025), vetoed (opens in new tab)
Its own words

Iowa Code 124.201(4): If any new substance is designated as a controlled substance under federal law and notice of the designation is given to the board, the board shall similarly designate as controlled the new substance under this chapter after the expiration of thirty days from publication in the federal register of a final order designating a new substance as a controlled substance

KansasKansas has no clause that follows a federal change. The Board of Pharmacy only reports proposed reschedulings to the legislature each year, so psilocybin stays in Schedule I until the legislature amends the act.DEA rule, then the legislatureWaiting. HB 2218, which would have listed the approved product in Schedule IV, was stricken from the House calendar on 19 February 2026.K.S.A. 65-4102(b) (opens in new tab)HB 2218 (2026), stricken from calendar (opens in new tab)
Its own words

K.S.A. 65-4102(b): Annually, the board shall submit to the speaker of the house of representatives and the president of the senate a report on substances proposed by the board for scheduling, rescheduling or deletion by the legislature

KentuckyA federal rescheduling follows automatically, with no waiting period: the drug is controlled in Kentucky in the same numerical schedule as the federal one. The Cabinet for Health and Family Services may instead regulate it into a more restrictive schedule.DEA ruleWaiting on an FDA approval.KRS 218A.020(3) (opens in new tab)902 KAR 55:015 (opens in new tab)
Its own words

KRS 218A.020(3)(a): (a) If any substance is designated or rescheduled as a controlled substance under the federal Controlled Substances Act, the drug shall be considered to be controlled at the state level in the same numerical schedule corresponding to the federal schedule.

902 KAR 55:015, Section 4(1): each substance that is scheduled or designated as a Schedule IV controlled substance under 21 C.F.R. 1308.14 shall be scheduled or designated at the state level as a Schedule IV controlled substance.

LouisianaThe health secretary may, in an adjudication, transfer a substance to match its DEA schedule, with no time limit, and a transfer leaves the statute's penalties unchanged. Whether the approved product counts instead as an addition, which the secretary must make, the text leaves open.DEA rule, then health secretaryWaiting on an FDA approval.La. R.S. 40:962(D) (opens in new tab)
Its own words

La. R.S. 40:962(D): In an adjudication, the secretary may transfer a controlled substance from one schedule to another schedule upon the basis of a finding ... that a transfer of any substance listed under R.S. 40:964 from one schedule to another schedule should be made in order to conform with the schedule in which the drug is placed by the Drug Enforcement Administration of the United States government.

La. R.S. 40:962(G): The reclassification of any controlled dangerous substance or its transfer from one schedule to another by the secretary or the state health officer shall not affect the penalties provided by this Part.

MaineMaine's drug schedules are set by statute for defining crimes, and none follows federal scheduling. Psilocybin stays in Schedule X, and the text does not say whether an approved prescription product containing it stays there or falls to Schedule Z.DEA rule, then the legislatureWaiting on an FDA approval.17-A M.R.S. 1102 (opens in new tab)
Its own words

17-A M.R.S. 1102: For the purposes of defining crimes under this chapter and of determining the penalties therefor, there are hereby established the following schedules, designated W, X, Y and Z.

17-A M.R.S. 1102(4)(A): All prescription drugs other than those included in schedules W, X or Y;

MarylandMaryland's Schedules II to V take in whatever the federal government designates in them, unless the Department objects, so a federal placement of the approved medicine follows automatically. The text does not say which schedule governs while psilocybin itself stays federally in Schedule I.DEA ruleWaiting on an FDA approval.Md. Code, Crim. Law 5-202(f) (opens in new tab)Md. Code, Crim. Law 5-405(a) (opens in new tab)
Its own words

Md. Code, Crim. Law 5-405(a): Schedule IV consists of each controlled dangerous substance: ... added to Schedule IV by the Department under ... designated as a Schedule IV controlled dangerous substance by the federal government unless the Department objects under

Md. Code, Crim. Law 5-202(f): A new substance that is designated as a controlled substance under federal law is a similarly controlled dangerous substance under this title unless the Department objects to the inclusion.

MassachusettsThe commissioner must act within 30 days only for a substance not yet scheduled or moved to a stricter schedule, and may move one to a lower schedule. Section 2(a) also has the state's schedules incorporate the federal schedules and any amendment of them. The text does not reconcile the two, or say whether the approved product counts as not yet scheduled.DEA rule, then the commissionerWaiting on an FDA approval.Mass. Gen. Laws c. 94C, s. 2(a1/2) (opens in new tab)Mass. Gen. Laws c. 94C, s. 2(a) (opens in new tab)
Its own words

Mass. Gen. Laws c. 94C, s. 2(a1/2): The commissioner may, pursuant to the provisions of chapter thirty-A, delete or reschedule all substances enumerated in the schedules established pursuant to the provisions of subsection (a),

Mass. Gen. Laws c. 94C, s. 2(a1/2): if any substance which has not been scheduled pursuant to the provisions of this section is designated a controlled substance ... or if any substance which has been scheduled ... is designated a controlled substance of greater abuse liability ... shall, not more than thirty days after publication of final notice in the federal register ... issue a regulation controlling the substance

Mass. Gen. Laws c. 94C, s. 2(a): the commissioner shall establish by regulations pursuant to the provisions of chapter thirty A five schedules incorporating the five schedules of controlled substances under the ''Comprehensive Drug Abuse, Prevention and Control Act of 1970'' or any amendment thereof

MichiganOnce the Board of Pharmacy is notified, the approved medicine must be scheduled in Michigan as it is federally, unless the board meets within 60 days of notice to decide whether to follow. The text sets no deadline for the scheduling itself.DEA rule, then Board of PharmacyWaiting on an FDA approval.MCL 333.7204 (opens in new tab)
Its own words

MCL 333.7204: If a substance is designated, rescheduled, or deleted as a controlled substance under federal law ... the substance must be similarly scheduled under section 7201 unless the administrator holds a board meeting not more than 60 days after notice is received to determine whether the substance should be similarly controlled under section 7201.

MinnesotaThe Board of Pharmacy may follow a federal rescheduling by an order that expires within 12 months and cannot be renewed. The text does not say how the change becomes permanent, since the board may not otherwise reschedule a Schedule I drug.DEA rule, then Board of PharmacyWaiting on an FDA approval.Minn. Stat. 152.02, subd. 12(a) (opens in new tab)
Its own words

Minn. Stat. 152.02, subd. 12(a): If any substance is designated, rescheduled, or deleted as a controlled substance under federal law, the Board of Pharmacy may similarly and temporarily control the substance under this chapter by issuing an order ... The order expires no later than 12 months after the date of issue and may not be renewed.

Minn. Stat. 152.02, subd. 8: The Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as provided in subdivision 12.

MississippiOnce the DEA schedules an FDA-approved crystalline polymorph psilocybin composition, it is automatically placed on the matching state schedule, with that schedule's penalties. This lasts only until a statute amends the schedule or the next regular legislative session ends, whichever comes first.DEA ruleIn force since 1 July 2026 and waiting. Once triggered, it holds only until the schedules are amended or the next regular session ends.Miss. Code 41-29-111(1)(d) (opens in new tab)SB 2056 (2026), Section 1 (opens in new tab)Read in the enacted bill; the code host refused automated readers.
Its own words

SB 2056 (2026), Section 1: any pharmaceutical composition of crystalline polymorph psilocybin that is approved by the United States Food and Drug Administration and is then scheduled by the United States Drug Enforcement Administration shall be automatically scheduled on the corresponding state schedule in Sections 41-29-113 through 41-29-121 and shall be subject to the fines and penalties of that state schedule.

SB 2056 (2026), Section 1: This automatic scheduling shall be effective from the date that the drug is designated on the federal schedule until the effective date of legislation amending the corresponding state schedule or until the conclusion of the next regular session of the Legislature, including the time period in which the bill is subject to veto by the governor, whichever is earlier.

MissouriOnce notified, the Department of Health and Senior Services must follow a federal rescheduling and submit emergency rules within 30 days of the DEA's final order, unless it objects. The text does not say if an interim final rule counts as a final order.DEA rule, then Department of Health and Senior ServicesWaiting on an FDA approval.Mo. Rev. Stat. 195.015.4 (opens in new tab)
Its own words

Mo. Rev. Stat. 195.015.4: the department of health and senior services shall similarly control the substance under this chapter and shall submit emergency rules to the secretary of state under section 536.025 within thirty days of publication in the federal register of a final order ... unless within that thirty-day period, the department of health and senior services objects to inclusion, rescheduling, or deletion.

MontanaOnce notified, the Board of Pharmacy must follow a federal rescheduling 30 days after the DEA's final order is published, unless it objects. The text does not say if an interim final rule counts as a final order.DEA rule, then Board of PharmacyWaiting on an FDA approval.Mont. Code Ann. 50-32-203 (opens in new tab)
Its own words

Mont. Code Ann. 50-32-203: If any drug is designated, rescheduled, or deleted as a "controlled substance" under federal law ... the board shall similarly control the drug under this chapter after the expiration of 30 days from publication in the Federal Register of a final order ... unless, within that 30-day period, the board objects to inclusion, rescheduling, or deletion.

NebraskaThe statute already takes an FDA-approved pharmaceutical composition of crystalline polymorph psilocybin out of Schedule I and lists it in Schedule IV, on FDA approval alone. Federal Schedule I still applies until the DEA's rule, and a different DEA schedule would need another statute.DEA ruleEnacted by LB 72, approved 25 February 2025, and in the current code. Waiting on an FDA approval.Neb. Rev. Stat. 28-405 (opens in new tab)LB 72 (2025) (opens in new tab)
Its own words

Neb. Rev. Stat. 28-405, Schedule I(c)(12): (12) Psilocybin. Psilocybin does not include any pharmaceutical composition of crystalline polymorph psilocybin approved by the federal Food and Drug Administration;

Neb. Rev. Stat. 28-405, Schedule IV(g): (g) Any pharmaceutical composition of crystalline polymorph psilocybin approved by the federal Food and Drug Administration.

NevadaNot read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand.Not read yetNot read yet.NRS 453.146 (opens in new tab)Not read yet
New HampshireOnce notified, the health and human services commissioner must follow a federal rescheduling 30 days after the DEA's final order is published, unless the commissioner objects. The text does not say if an interim final rule counts as a final order.DEA rule, then health and human services commissionerWaiting on an FDA approval.RSA 318-B:1-a, V (opens in new tab)
Its own words

RSA 318-B:1-a, V: If any substance is designated, rescheduled, or deleted as a controlled substance under federal law ... the commissioner shall similarly control the substance under this chapter after the expiration of 30 days from publication in the Federal Register of a final order ... unless, within that 30 day period, the commissioner objects to inclusion, rescheduling, or deletion.

New JerseyNot read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand.Not read yetNot read yet.N.J.S.A. 24:21-3 (opens in new tab)Not read yet
New MexicoThe Board of Pharmacy may, by regulation after a hearing, control a substance designated under federal law, with no time limit. The clause names designation only, and FDA-approved psilocybin products are exempt from the state's Medical Psilocybin Act.DEA rule, then Board of PharmacyWaiting on an FDA approval.NMSA 1978, 30-31-3(C) (opens in new tab)NMSA 1978, 26-2D-4 (opens in new tab)
Its own words

NMSA 1978, 30-31-3(C): If any substance is designated as a controlled substance under federal law and notice is given to the board, the board may, by regulation, similarly control the substance under the Controlled Substances Act after providing for a hearing pursuant to the Uniform Licensing Act.

NMSA 1978, 26-2D-4: Federal food and drug administration-approved products that contain psilocybin shall be exempt from the Medical Psilocybin Act

New YorkIf the DEA moves the approved product out of Schedule I, the health commissioner must reclassify it by regulation or emergency regulation, into the federal schedule or a less restrictive one, or exempt it. The text sets no deadline.DEA rule, then health commissionerWaiting on an FDA approval.N.Y. Pub. Health Law 3307(5) (opens in new tab)Read in the enacted bill; the code host refused automated readers.
Its own words

S8618 (2022), the Legislature's summary: Requires the commissioner of health by regulation or emergency regulation, to reclassify any compound, mixture or preparation containing any substance listed in Schedule I ... as a Schedule II, III, IV or V substance, or exempt it, if that same compound, mixture or preparation is redesignated or rescheduled other than under Schedule I under the federal Controlled Substances Act

North CarolinaNot read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand.Not read yetNot read yet.N.C. Gen. Stat. 90-88 (opens in new tab)Not read yet
North DakotaThe statute already lists COMP360, or its FDA-approved trade name, in state Schedule IV, but federal Schedule I applies until the DEA's rule. If the DEA chooses another schedule, the general clause directs the Board of Pharmacy to follow it after 30 days.DEA ruleIn force since 26 March 2025. Waiting on an FDA approval.N.D.C.C. 19-03.1-02(4) (opens in new tab)N.D.C.C. 19-03.1-11(7) (opens in new tab)SB 2064 (2025) (opens in new tab)
Its own words

N.D.C.C. 19-03.1-11(7): 7. Hallucinogenic substances. Pharmaceutical composition of crystalline polymorph psilocybin, known as COMP360 or any such trade name approved for COMP360 by the United States food and drug administration.

N.D.C.C. 19-03.1-02(4): If any substance is designated, rescheduled, or deleted as a controlled substance under federal law ... the board shall similarly control the substance under this chapter after the expiration of thirty days from publication in the federal register of a final order ... unless within that thirty-day period, the board objects to inclusion, rescheduling, or deletion.

OhioNot read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand.Not read yetNot read yet.R.C. 3719.43 (opens in new tab)Not read yet
OklahomaUnder a general rule for FDA-approved prescription drugs, the approved medicine leaves Schedule I and follows federal law once the DEA issues a notice, final rule or interim final rule rescheduling it, unless and until the Board of Pharmacy acts.DEA ruleWaiting on an FDA approval.63 O.S. 2-204(H) (opens in new tab)63 O.S. 2-201 (opens in new tab)
Its own words

63 O.S. 2-204(H): Any prescription drug approved by the federal Food and Drug Administration ... that is designated, rescheduled, or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I ... upon the issuance of a notice, final rule, or interim final rule ... unless and until the State Board of Pharmacy takes action

OregonOregon's schedules follow the federal ones through Board of Pharmacy rules that cite dated federal texts. On the rules' words, a DEA placement after those dates enters the state list only when the board amends them, which it may do with no deadline.DEA rule, then Board of PharmacyWaiting on an FDA approval.ORS 475.005(6)(a), 475.035(2) (opens in new tab)OAR 855-080-0020 (opens in new tab)
Its own words

OAR 855-080-0020: those drugs and their immediate precursors classified in Schedules I through V under the Federal Controlled Substances Act, 21 USC 811 (v. 02/26/2026), 21 USC 812 (v. 02/26/2026) and as amended by the board pursuant to ORS 475.035 are the controlled substances

OAR 855-080-0021(1): Schedule I consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in 21 CFR 1308.11 (v. 04/01/2025)

PennsylvaniaThe Secretary of Health may reschedule a substance to match federal law on finding that public health and safety will not be harmed, and a move to a lower schedule may take effect when published in the Pennsylvania Bulletin.DEA rule, then Secretary of HealthWaiting on an FDA approval.35 P.S. 780-103(c)(1) (opens in new tab)
Its own words

35 P.S. 780-103(c)(1): if the secretary finds that the health and safety of the public will not be adversely affected, the secretary may: ... Reschedule any controlled substance to coincide with Federal law ... The rescheduling of a controlled substance to a lower schedule may take effect upon publication in the Pennsylvania Bulletin.

Rhode IslandRhode Island's list of controlled substances is the current Title 21 of the federal regulations, which the director of health must reference, so a DEA placement changes it with no waiting period unless the director objects.DEA ruleWaiting on an FDA approval.R.I. Gen. Laws 21-28-2.01(a)(1), (c) (opens in new tab)
Its own words

R.I. Gen. Laws 21-28-2.01(a)(1), (c): The director of the department of health shall control all substances enumerated in the most current version of Title 21 of the Code of Federal Regulations (C.F.R.) ... shall reference the current version of Title 21 of the C.F.R. as the current list of substances designated, rescheduled, or deleted as a controlled substance for the state.

R.I. Gen. Laws 21-28-2.01(c): If the director objects to inclusion, rescheduling, or deletion of any substance under the current federal law ... the director shall file that decision with the secretary of state

South CarolinaThe Director of the Department of Public Health must mirror a federal rescheduling within 30 days after the DEA's final order is published, if an interim final rule counts as one. The change has the force of law unless the General Assembly overturns it.DEA rule, then Department of Public HealthWaiting on an FDA approval.S.C. Code 44-53-160(C) (opens in new tab)
Its own words

S.C. Code 44-53-160(C): If a substance is added, deleted, or rescheduled as a controlled substance pursuant to federal law or regulation, the Director of the Department of Public Health shall within thirty days after publication in the federal register of the final order ... add, delete, or reschedule the substance in the appropriate schedule.

S.C. Code 44-53-160(C): The addition, deletion, or rescheduling of a substance by the department pursuant to this subsection has the full force of law unless overturned by the General Assembly.

South DakotaThe statute already takes an FDA-approved crystalline polymorph psilocybin drug product out of Schedule I and lists it in Schedule IV, on FDA approval alone. Federal Schedule I still applies until the DEA's rule, and only the legislature can follow a different federal schedule.DEA ruleIn force since 1 July 2026, the default date for an act that names none. Waiting on an FDA approval.SDCL 34-20B-27 (opens in new tab)SDCL 34-20B-25(65) (opens in new tab)HB 1099 (2026) (opens in new tab)
Its own words

SDCL 34-20B-14(18): (18) Psilocybin, except the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration;

SDCL 34-20B-25(65): (65) The pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration.

TennesseeNot read yet. The state’s official code host would not serve it to us, so this row waits for a reading by hand.Not read yetNot read yet.Tenn. Code Ann. 39-17-403(d)(1) (opens in new tab)Not read yet
TexasThe state health commissioner must reschedule the approved medicine after a 30-day period that starts the day after the DEA's final order is published, unless the commissioner objects. Psilocybin also stays listed by statute in Penalty Group 2, a list outside this clause.DEA rule, then health commissionerWaiting on an FDA approval.Tex. Health & Safety Code 481.034(g) (opens in new tab)Tex. Health & Safety Code 481.103 (opens in new tab)
Its own words

Tex. Health & Safety Code 481.034(g): After the expiration of a 30-day period beginning on the day after the date of publication in the Federal Register of a final order designating a substance as a controlled substance or rescheduling or deleting a substance, the commissioner similarly shall designate, reschedule, or delete the substance, unless the commissioner objects during the period.

Tex. Health & Safety Code 481.103(a)(1): Penalty Group 2 consists of: (1) any quantity of the following hallucinogenic substances ... Psilocin; and Psilocybin;

UtahA federal rescheduling follows automatically: once the federal government places an FDA-approved composition of a Schedule I substance in a schedule other than Schedule I, Utah deems it scheduled in that same schedule, with no state act and no waiting period.DEA ruleIn force since 6 May 2026. Waiting on an FDA approval.Utah Code 58-37-108(3) (opens in new tab)S.B. 83 (2026) (opens in new tab)
Its own words

Utah Code 58-37-108(3)(b): If the federal government schedules a pharmaceutical composition of a Schedule I controlled substance ... in a schedule that is not Schedule I, that pharmaceutical composition is deemed scheduled under this section in the same schedule that the pharmaceutical composition is scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Part 1308.

Utah Code 58-37-108(3)(a): "pharmaceutical composition" means a drug that has United States Food and Drug Administration approval under 21 U.S.C. Sec. 355 following clinical trials.

VermontVermont keeps no drug schedules, so it has nothing to reschedule. Psilocybin is a hallucinogenic drug by statute, and section 4214(a) lets a licensed physician prescribe, administer and dispense regulated drugs, a class that includes hallucinogenic drugs. The text does not say how federal scheduling bears on that.DEA ruleWaiting on an FDA approval.18 V.S.A. 4201(10) (opens in new tab)18 V.S.A. 4214(a) (opens in new tab)
Its own words

18 V.S.A. 4201(10): (10) “Hallucinogenic drugs” means stramonium, mescaline or peyote, lysergic acid diethylamide, and psilocybin

18 V.S.A. 4201(29): (29) “Regulated drug” means: (A) a narcotic drug; (B) a depressant or stimulant drug, other than methamphetamine; (C) a hallucinogenic drug

18 V.S.A. 4214(a): (a) A physician or dentist licensed under this chapter, in good faith and in the course of his or her professional practice only, may prescribe, administer, and dispense regulated drugs

VirginiaIf the FDA approves a psilocybin formulation for a health care professional to give in a health care setting, the Board of Pharmacy must reschedule it at its next quarterly meeting after 30 days from the DEA's final or interim final order or rule.DEA rule, then Board of PharmacyEnacted in 2026 as chapters 305 and 306. Waiting on an FDA approval.Va. Code 54.1-3443(E) (opens in new tab)2026 Va. Acts ch. 305 (opens in new tab)2026 Va. Acts ch. 306 (opens in new tab)
Its own words

2026 Va. Acts ch. 305: Upon approval by the U.S. Food and Drug Administration (FDA) of a formulation of psilocybin designed to be administered by a health care professional in a health care setting, the Board of Pharmacy shall reschedule such formulation of psilocybin ... at its next quarterly meeting following the expiration of 30 days from publication in the Federal Register of a final or interim final order or rule

Va. Code 54.1-3443(E): the Board may similarly control the substance under this chapter after the expiration of 30 days from publication in the Federal Register of a final or interim final order or rule

WashingtonThe Pharmacy Quality Assurance Commission must follow a federal rescheduling 30 days after the DEA's final order is published, unless it or any interested party objects. The text does not say if an interim final rule counts as a final order.DEA rule, then Pharmacy Quality Assurance CommissionWaiting on an FDA approval.RCW 69.50.201(d) (opens in new tab)
Its own words

RCW 69.50.201(d): If a substance is designated, rescheduled, or deleted as a controlled substance under federal law, ... the commission shall similarly control the substance under this chapter after the expiration of thirty days from the date of publication in the federal register of a final order ... unless within that thirty-day period, the commission or an interested party objects

West VirginiaOnce the FDA approves and the DEA reschedules a drug containing an organic psilocybin substance or crystalline polymorph psilocybin, it becomes lawful to prescribe, distribute and market it, and the Schedule I psilocybin entry excepts it. The text does not say which state schedule then applies.DEA ruleIn force since 12 June 2026. Waiting on an FDA approval.W. Va. Code 60A-2-201(d) (opens in new tab)W. Va. Code 60A-2-201(g) (opens in new tab)SB 906 (2026) (opens in new tab)
Its own words

W. Va. Code 60A-2-201(g): (g) Notwithstanding §60A-2-204(d) of this code, if a drug that contains, an organic psilocybin substance or the pharmaceutical composition of crystalline polymorph psilocybin, is approved by the United States Food and Drug Administration and rescheduled by the United States Drug Enforcement Administration it shall be lawful to prescribe, distribute, and market based upon the recommendations of the United States Food and Drug Administration.

W. Va. Code 60A-2-201(d): If any substance is designated, rescheduled, or deleted as a controlled substance under federal laws and notice thereof is given to the Board of Pharmacy, the board shall recommend similar control of such substance to the Legislature

W. Va. Code 60A-2-204(d): (d) Hallucinogenic substances. ... Psilocybin; except as provided for in §60A-2-201(g) of this code; Psilocyn;

WisconsinOnce notified, the Controlled Substances Board must follow a federal rescheduling by affirmative action 30 days after the DEA's final order is published, unless it or an interested party objects. The text does not say if an interim final rule counts as a final order.DEA rule, then Controlled Substances BoardWaiting on an FDA approval.Wis. Stat. 961.11(4) (opens in new tab)
Its own words

Wis. Stat. 961.11(4): the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order ... unless within that 30-day period, the board or an interested party objects to the treatment of the substance.

WyomingThe attorney general, as commissioner, must control the approved medicine as federal law does, by emergency rule, within 30 days of notice and no later than 30 days after the change first appears in the Federal Register, unless the commissioner objects.DEA rule, then attorney generalWaiting on an FDA approval.Wyo. Stat. 35-7-1011(d) (opens in new tab)
Its own words

Wyo. Stat. 35-7-1011(d): If any substance is designated, rescheduled, or deleted as a controlled substance under federal law the commissioner shall control the substance under this act in the same manner as federal law within thirty (30) days after receiving notice of the change but not later than thirty (30) days after the first publication of the change in the Federal Register.

Changes to this page

  1. Named the 2026 act behind Illinois’s day-30 rule, P.A. 104-0819, in force since 7 August, and the hearing clock an objection starts. Arizona’s row now gives the date its 2026 law took effect, 12 September, and the Title 13 section that keeps a lawful holder outside the dangerous-drug offense.

  2. Corrected five rows. Arizona and Colorado passed laws in 2026, SB 1188 and SB 26-031, under which an FDA-approved drug the DEA reschedules takes the federal schedule with no further state act; our first reading missed both. Vermont’s row now cites section 4214(a), which lets a physician prescribe regulated drugs, and no longer lists its legislature as a step. The Massachusetts row adds section 2(a), and the West Virginia row says its Schedule I psilocybin entry excepts the approved drug.

  3. First version. Every state’s scheduling law read on its own host, the federal step read at govinfo and eCFR, and the fourteen psilocybin measures read again.

Get an email when this table changes

One email when the FDA acts on a psilocybin medicine and one when the DEA’s rule is published, each saying which rows of this table changed. The same list gets our monthly roundup.

We never send spam or share your address, and you can unsubscribe at any time, as the privacy statement explains.

How we read these laws Every state’s scheduling law, read on its own host and checked word for word.

For each state and the District of Columbia we read the part of its controlled-substances act that says how its drug schedules change, usually a section modelled on the 1970 Uniform Controlled Substances Act, and any provision that names psilocybin or drugs the FDA has approved. Each was read on the state’s own legislature or code host on the date in its row, and a script then fetched every quoted passage again and matched it word for word before it entered this table.

The column headed What it waits on lists what still has to happen, after the FDA approves, before the medicine sits in a lower schedule under both federal and the state’s law: the DEA’s rule, and then any state board, official or legislature the state’s text names. Where a state already wrote the medicine into its own schedule, only the DEA’s rule remains.

Most of these clauses were written before 2015, when Congress gave the DEA its interim final rule for newly approved drugs. Many speak of a final order. Whether an interim final rule counts as one is a question of each state’s law that this table does not answer, and the rows that turn on it say so.

The fourteen measures written for a psilocybin medicine, eleven of them enacted, were first read for our analysis of them in September and were read again for this table.

Five states’ official codes could not be read from our network. Nevada’s, North Carolina’s and Ohio’s refuse it even in an ordinary browser, New Jersey’s legislature site does not answer it, and Tennessee’s official code opens only behind a terms page that we leave to a person to accept. Their rows say Not read yet and link the official page, and each is queued for a reading by hand. A state we could not read is never recorded as having no clause.

Where an official code host refused us but the state’s own pharmacy board publishes the act, we read the board’s copy and the row says so. The quoted words are always the words at the link in the row.

This table reads what each statute says. It does not say how a state’s officials will apply it, and it is not legal advice.

Sources

This table reads each statute’s words. It is not legal advice, and where the words leave a question open the row says so. Corrections go to the corrections desk.